Breakthroughs in Pancreatic Cancer Treatment: Radioactive Rods and New Drugs Double Survival in Europe

Two experimental drugs have shown significant promise in extending survival for patients with pancreatic cancer, one of the most lethal forms of the disease, according to recent clinical trial results reported in April 2026.

Revolution Medicines announced on April 13 that its oral medication, daraxonrasib, helped patients with previously treated metastatic pancreatic cancer survive an average of 13.2 months after starting treatment, compared to 6.7 months for those receiving standard chemotherapy. This represents a doubling of survival time and a 60 percent reduced risk of death in the Phase III trial involving 500 participants.

Dr. Brian Wolpin, professor of medicine at Harvard Medical School and principal investigator for the trial, described the results as a “very important advance for the field” that he expects will be practice-changing for physicians and improve care for patients with metastatic pancreatic cancer.

The following day, research supported by Actuate Therapeutics was published in Nature Medicine showing that its intravenous drug, elraglusib, also doubled one-year survival for patients compared to those receiving standard chemotherapy in an earlier-stage Phase II trial. The company plans to continue studying the drug in more patients.

Both drugs represent a meaningful step forward in a disease area that has seen limited progress despite improvements in survival rates since the 1970s, which have plateaued in recent years. Pancreatic cancer remains the third-leading cause of cancer deaths in the United States, with an estimated 67,530 cases and 52,740 deaths expected in 2026 according to the American Cancer Society.

For patients with late-stage pancreatic cancer, the survival rate drops to just about one year after diagnosis, according to Johns Hopkins Medicine, and the five-year survival rate remains below 20 percent, as reported by the Pancreatic Cancer Action Network. Immune-based therapies and personalized treatments based on genetic mutations have not proven effective against pancreatic cancer, making these new developments particularly significant.

Revolution Medicines plans to submit the daraxonrasib trial results to the U.S. Food and Drug Administration (FDA) for approval and has received a Commissioner’s National Priority Voucher, which ensures an expedited review timeline. Actuate Therapeutics’ elraglusib is still in earlier stages of development.

Taken together, the results offer much-needed hope to the pancreatic cancer community, which has historically had fewer treatment options compared to patients with other cancers. While the improvements in survival time may appear modest, researchers emphasize that such advances are critical first steps toward more meaningful long-term benefits.